Fig. 8: BRI-50460 protected amyloid-42 oligomer-synaptic and dendritic reduction in neurons derived from human iPSCs. | npj Drug Discovery

Fig. 8: BRI-50460 protected amyloid-42 oligomer-synaptic and dendritic reduction in neurons derived from human iPSCs.

From: Development of potent, selective cPLA2 inhibitors for targeting neuroinflammation in Alzheimer’s disease and other neurodegenerative disorders

Fig. 8

A Representative images of the immunofluorescent staining of synapsin (green), CamKII (red), and MAP2 (white) in iPSC-derived neurons treated with 2.5 μM Aβ42 oligomers (Aβ42O) with or without 1 μM BRI-50460 for 72 hours. B Enlarged images of the boxed dendrites in A. BRI-50460 (460) reduced Aβ42O-induced reduction of synapsin puncta (C), CamKIIa (D) and MAP2 (E) density area occupied in neurons derived from human iPSCs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Analyzed image numbers for CamKIIα and MAP2 include CTRL (n = 12), Aβ42 O (n = 13), 460 (n = 13), for synapsin puncta include CTRL (194), Aβ42O (n = 68), 460 (n = 167).

Back to article page